Chat with this insight
Save time and jump to the most important pieces.
Recent Analyst Ratings for $ALXO
Date | Price Target | Rating | Analyst |
---|---|---|---|
12/19/2024 | $12.00 → $2.00 | Buy → Hold | Jefferies |
3/8/2024 | $10.00 → $14.00 | Buy → Hold | Stifel |
12/8/2023 | $8.00 → $18.00 | Hold → Buy | Jefferies |
3/1/2022 | $60.00 → $36.00 | Buy | Stifel |
12/22/2021 | $65.00 → $25.00 | Buy → Hold | Jefferies |
9/30/2021 | $106.00 | Buy | Stifel |
ALX Oncology to Host Virtual R&D Day on March 5, 2025
SOUTH SAN FRANCISCO, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (NASDAQ:ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients' lives, today announced that it will host a virtual Research and Development (R&D) Day webcast on Wednesday, March 5, 2025, at 6:00 a.m. PT/9:00 a.m. ET. The virtual webcast event will focus on information and updates related to the company's pipeline, lead investigational CD47-blocker evorpacept, as well as business and financial updates. R&D Day Webcast InformationThe ALX Oncology virtual R&D Day will be webcast live and a repl
ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer
Oral presentation at 2025 ASCO Gastrointestinal Cancers Symposium today highlights evorpacept as the first CD47 blocker to show substantial tumor response and a well-tolerated safety profile in a prospective randomized trialGreatest benefit observed among patients with confirmed HER2-positive cancer, as demonstrated by either fresh biopsy or ctDNA HER2-expression, with confirmed ORR of 48.9% and mDOR of 15.7 months vs. 24.5% ORR and mDOR of 9.1 months in the control group, and a PFS Hazard Ratio of 0.64Company to host conference call and investor webcast today at 1:00 PM PT/4:00 PM ET SOUTH SAN FRANCISCO, Calif., Jan. 23, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules
SOUTH SAN FRANCISCO, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings, Inc. ("ALX Oncology" or the "Company"), (NASDAQ:ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients' lives, today announced that effective January 21, 2025, the Compensation Committee of the Board of Directors of ALX Oncology granted an inducement stock option to purchase a total of 600,000 shares of ALX Oncology's common stock to Harish Shantharam, the Company's Chief Financial Officer, in connection with the commencement of his employment. Mr. Shantharam's inducement stock option is subject to the terms of the ALX Oncology Ho
ALX Oncology downgraded by Jefferies with a new price target
Jefferies downgraded ALX Oncology from Buy to Hold and set a new price target of $2.00 from $12.00 previously
ALX Oncology downgraded by Stifel with a new price target
Stifel downgraded ALX Oncology from Buy to Hold and set a new price target of $14.00 from $10.00 previously
ALX Oncology upgraded by Jefferies with a new price target
Jefferies upgraded ALX Oncology from Hold to Buy and set a new price target of $18.00 from $8.00 previously
Director Hemrajani Rekha bought $46,404 worth of shares (30,000 units at $1.55), increasing direct ownership by 1,000% to 33,000 units (SEC Form 4)
4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)
Amendment: CHIEF FINANCIAL OFFICER Garcia Peter S bought $102,338 worth of shares (12,000 units at $8.53), increasing direct ownership by 11% to 122,348 units (SEC Form 4)
4/A - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)
CHIEF FINANCIAL OFFICER Garcia Peter S bought $102,338 worth of shares (12,000 units at $8.53), increasing direct ownership by 11% to 122,348 units (SEC Form 4)
4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)
SEC Form 4 filed by Director Hemrajani Rekha
4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)
SEC Form 4 filed by Director Garland J. Scott
4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)
SEC Form 4 filed by Director Goodman Corey S
4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)
Amendment: SEC Form SCHEDULE 13G/A filed by ALX Oncology Holdings Inc.
SCHEDULE 13G/A - ALX ONCOLOGY HOLDINGS INC (0001810182) (Subject)
ALX Oncology Holdings Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
8-K - ALX ONCOLOGY HOLDINGS INC (0001810182) (Filer)
SEC Form 8-K filed by ALX Oncology Holdings Inc.
8-K - ALX ONCOLOGY HOLDINGS INC (0001810182) (Filer)
ALX Oncology Announces Further Additions to Leadership Team and Board of Directors, Appointing Harish Shantharam as Chief Financial Officer and Adding Barbara Klencke and Chris Takimoto to Board of Directors
Mr. Shantharam is a proven biotech industry executive with over two decades of senior leadership experience in finance, commercial and corporate operationsDr. Klencke is a seasoned clinical leader in oncology drug development with more than 20 years of industry experienceDr. Takimoto brings a distinguished track record in oncology and drug development with 17 years of industry experience SOUTH SAN FRANCISCO, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (NASDAQ:ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients' lives, today announced the appointmen
ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer
SOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or "the Company") (NASDAQ:ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer in new ways and extend patients' lives, announced today the appointment of Alan Sandler, M.D., as Chief Medical Officer. "Dr. Sandler's breadth of experience and demonstrated leadership capabilities across oncology and drug development, as well as his in-depth knowledge of ALX Oncology while he was a member of our Board, will be instrumental in helping us achieve our near- and longer-term objectives," said Jason Lettmann, Chief Executive Officer at
ALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or "the Company") (NASDAQ:ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today reported financial results for the second quarter ended June 30, 2024, and provided a corporate update. "Our team continues to make significant progress in the advancement of our evorpacept development pipeline across multiple oncology indications," said Jason Lettmann, Chief Executive Officer of ALX Oncology. "Data readouts across our Phase 1 and 2 clinical trials highlight the potential of evorpacept as a disruptive therapy in combination with anti
ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer
Oral presentation at 2025 ASCO Gastrointestinal Cancers Symposium today highlights evorpacept as the first CD47 blocker to show substantial tumor response and a well-tolerated safety profile in a prospective randomized trialGreatest benefit observed among patients with confirmed HER2-positive cancer, as demonstrated by either fresh biopsy or ctDNA HER2-expression, with confirmed ORR of 48.9% and mDOR of 15.7 months vs. 24.5% ORR and mDOR of 9.1 months in the control group, and a PFS Hazard Ratio of 0.64Company to host conference call and investor webcast today at 1:00 PM PT/4:00 PM ET SOUTH SAN FRANCISCO, Calif., Jan. 23, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology
ALX Oncology to Host Virtual Company Event Highlighting Updated Data from ASPEN-06 Phase 2 Trial Presented at 2025 ASCO GI
Webcast on January 23 at 1:00 p.m. PT/4:00 p.m. ET will review updated data from trial evaluating CD47-blocker evorpacept in HER2-positive gastric cancer SOUTH SAN FRANCISCO, Calif., Jan. 21, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (NASDAQ:ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients' lives, today announced that the company will host a virtual event on Thursday, January 23, at 1:00 p.m. PT/4:00 p.m. ET to discuss updated data from the ASPEN-06 Phase 2 clinical trial evaluating the company's investigational CD47-blocker evorpacept in patients with previou
ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer
Evorpacept is the first CD47 blocker to show durable clinical benefit and a well-tolerated safety profile in a prospective randomized trial Evorpacept combination achieved a confirmed overall response rate (ORR) of 40.3% compared to 26.6% for the control arm and demonstrated a median duration of response of 15.7 months compared to 7.6 months in the full trial populationIn the pre-specified population of patients with fresh HER2-positive biopsies, evorpacept combination showed the greatest benefit with ORR of 54.8% vs. 23.1% in the control, suggesting HER2-expression strongly correlates with evorpacept efficacy and validating its mechanism of actionCompany to host conference call and
Amendment: SEC Form SC 13G/A filed by ALX Oncology Holdings Inc.
SC 13G/A - ALX ONCOLOGY HOLDINGS INC (0001810182) (Subject)
Amendment: SEC Form SC 13G/A filed by ALX Oncology Holdings Inc.
SC 13G/A - ALX ONCOLOGY HOLDINGS INC (0001810182) (Subject)
Amendment: SEC Form SC 13G/A filed by ALX Oncology Holdings Inc.
SC 13G/A - ALX ONCOLOGY HOLDINGS INC (0001810182) (Subject)